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Abstract
Nicotinamide (Nam) phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in mammalian NAD synthesis,
catalyzing nicotinamide mononucleotide (NMN) formation from Nam and 5-phosphoribosyl 1-pyrophosphate (PRPP).
NAMPT has also been described as an adipocytokine visfatin with a variety of actions, although physiological significance of
this protein remains unclear. It has been proposed that possible actions of visfatin are mediated through the extracellular
formation of NMN. However, we did not detect NMN in mouse blood plasma, even with a highly specific and sensitive liquid
chromatography/tandem mass spectrometry. Furthermore, there is no or little ATP, the activator of NAMPT, in extracellular
spaces. We thus questioned whether visfatin catalyzes the in situ formation of NMN under such extracellular milieus. To
address this question, we here determined Km values for the substrates Nam and PRPP in the NAMPT reaction without or
with ATP using a recombinant human enzyme and found that 1 mM ATP dramatically decreases Km values for the
substrates, in particular PRPP to its intracellular concentration. Consistent with the kinetic data, only when ATP is present at
millimolar levels, NAMPT efficiently catalyzed the NMN formation at the intracellular concentrations of the substrates. Much
lower concentrations of Nam and almost the absence of PRPP and ATP in the blood plasma suggest that NAMPT should not
efficiently catalyze its reaction under the extracellular milieu. Indeed, NAMPT did not form NMN in the blood plasma. From
these kinetic analyses of the enzyme and quantitative determination of its substrates, activator, and product, we conclude
that visfatin does not participate in NMN formation under the extracellular milieus. Together with the absence of NMN in
the blood plasma, our conclusion does not support the concept of ‘‘NAMPT-mediated systemic NAD biosynthesis.’’ Our
study would advance current understanding of visfatin physiology.
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Introduction
In mammalian cells, NAD is synthesized through the de novo
pathway from tryptophan or salvage pathways from nicotinamide
(Nam) and nicotinic acid (NA) [1]. The salvage synthesis is initiated
by the addition of a phosphoribosyl moiety from 5-phosphoribosyl 1-
pyrophosphate (PRPP) to the respective precursors yielding the
corresponding Nam and NA mononucleotides (NMN and NaMN) in
the reactions catalyzed by the rate-limiting enzymes Nam phosphor-
ibosyltransferase (NAMPT) and NA phosphoribosyltransferase
(NAPRT), respectively (Fig. 1), using ATP as the activator [2–6].
In addition to being an intracellular NAD synthetic enzyme,
NAMPT, originally identified as pre-B cell colony enhancing
factor [7], has also been described as a novel adipocytokine visfatin
[8], with a potential link to obesity, type 2 diabetes, and
inflammatory diseases [8–11]. However, because of markedly
conflicting associations between visfatin and these diseases in
subsequent clinical studies [12,13], the physiological significance of
this protein remains largely unclear.
Revollo et al. have proposed that extracellular visfatin acts
through ‘‘NAMPT-mediated systemic NAD biosynthesis’’ [9,14].
In this proposal, it is hypothesized that Nam in blood circulation is
converted to NMN by visfatin, and the resulting NMN is
distributed to tissues, transported to the inside of cells, and
converted to NAD to elicit reported biological effects. Subsequent
studies have also suggested possible extracellular conversion of
Nam to NMN by visfatin and novel functions of the resultant
NMN [11,15]. However, extracellular spaces are thought to
contain little or no ATP [16]. We thus questioned whether visfatin
is enzymatically active under such extracellular milieus. Indeed,
the in situ formation of NMN by visfatin under the extracellular
environments has not been directly investigated [9,11], although
enzyme activity of the secreted NAMPT was demonstrated under
an in vitro condition with a sufficiently high concentration of ATP
[9].
To address our question, we first determined Km values for the
substrates Nam and PRPP in the NAMPT reaction using a
recombinant human enzyme in the absence or presence of ATP.
We then evaluated NAMPT activity under the intra- and
extracellular milieus, based on kinetic parameters as well as the
actual intra- and extracellular concentrations of the substrates and
ATP we obtained in this study. We finally determined directly
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14C]Nam (50 mCi/mmol) and [carboxyl-
14C]NA
(50 mCi/mmol) were purchased from American Radiolabeled
Chemical Inc. (St. Louis, MO, USA). ATP, PRPP, and firefly
luciferase and luciferin were purchased from Oriental Yeast
(Tokyo, Japan), Sigma (St. Louis, MO, USA), and Wako Pure
Chemical Industries (Osaka, Japan), respectively.
Expression of wild-type human NAMPT and wild-type
and mutant human NAPRT
Recombinant NAMPT and NAPRT were obtained as de-
scribed previously [17]. The vector used to express mutant
NAPRT, in which His-213 is replaced by Asn, was produced using
a pET22b plasmid vector carrying wild-type NAPRT [17] and
primers 59-C GGG ACC CTG GCC aac TCC TTC GTC AC-39
and 59-GT GAC GAAGGA gtt GGC CAG GGT CCC G-39,
where the altered codon is indicated by lower-case italics. The
mutant enzyme was expressed and purified as described previously
[17].
NAMPT and NAPRT assays
Enzyme preparations were incubated with PRPP and
[
14C]Nam (50 mCi/mmol) or [
14C]NA (50 mCi/mmol) with a
standard reaction mixture (30 ml) containing 50 mM Tris-Cl
2
(pH 7.5), 10 mM MgCl2, 2.5 mM dithiothreitol (DTT), and
1.5 mg bovine serum albumin (BSA) in the presence or absence
of specific concentrations of ATP. After incubating at 37uC for a
given time, the reaction was boiled for 60 sec, and NMN and
NaMN formed were separated by thin layer chromatography and
quantified as described previously [17]. For kinetic analyses,
enzymes were incubated with specific concentrations of PRPP
together with Nam or NA in a standard reaction mixture with or
without ATP at 37uC. The initial velocity was plotted against the
concentration of the substrate. The curves were fitted using the
non-linear regression method (DeltaGraph 5), from which the Km
and Vmax for each reaction were derived.
Preparation of mouse blood plasma
The protocol of blood plasma preparation was approved by the
ethical committee for animal experiments of Shimane University
(Permit Numbers: IZ22–43, IZ23–38), in accordance with the
Guidelines for Animal Experimentation of the Japanese Associa-
tion for Laboratory Animal Science. All efforts were made to
minimize suffering of the animals. Blood from 6–13 week-old
C57/BL mice was drawn into heparinized syringes under sodium
pentobarbital anesthesia. Unless otherwise stated, the blood was
immediately mixed with 1/50 volume of 125 mM EDTA/EGTA.
After centrifugation at 1,5006g at 4uC for 7 min, the supernatant
was collected and used as freshly prepared plasma.
Determination of plasma concentrations of Nam, PRPP,
ATP, and NMN
Plasma concentrations of Nam and NMN were determined by
liquid chromatography/tandem mass spectrometry (LC/MS/MS)
analysis. The fresh plasma was immediately mixed with an equal
volume of 0.5 N perchloric acid (PCA). After centrifuging at
15,0006 g for 5 min, supernatant was neutralized by adding an
equal volume of 1 M ammonium formate (pH 6.4). The amounts
of Nam and NMN in the supernatant were determined, using a
triple quadrupole mass spectrometer (API3000, Applied Biosys-
tems, Foster City, CA, USA), as described previously [18].
Plasma PRPP levels were determined by NAPRT assay as
follows. The fresh plasma was immediately boiled for 60 sec,
cooled on ice, and centrifuged. The supernatant (5–10 ml) was
incubated with 20 mM[
14C]NA (50 mCi/mmol), recombinant
NAPRT (0.5 mg), 50 mM Tris-Cl
2 (pH 7.5), 10 mM MgCl2,
2.5 mM DTT, 1 mM ATP, and 1.5 mg BSA in a final volume of
30 ml. After incubating at 37uC for 15 min, the reaction was boiled
for 60 sec and the amount of NaMN formed was determined using
thin layer chromatography assay, as described above. A linear
relationship was observed between the amount of PRPP added to
the plasma (0.05–5 mM) and that of NaMN formed.
Plasma ATP levels were determined by luciferin/luciferase
assay. The fresh plasma was immediately mixed with an equal
volume of 0.5 N PCA. After centrifuging, supernatant was
neutralized by ammonium formate and diluted 20-fold with
H2O. The luciferin/luciferase mixture (430 mM luciferin, 8.6 mg/
ml luciferase, 22 mM Tris-Cl
2 (pH 7.8), 8.6 mM MgSO4,
0.43 mM EDTA, 4.3 mM DTT, 86 mM sodium pyrophosphate,
and 2.2 mg/ml BSA) was added to samples, and the sample
luminescence was compared with an ATP standard curve.
Determination of degrading activity against PRPP, ATP,
and NMN in the plasma
Fresh plasma prepared without the addition of EDTA/EGTA
was incubated with PRPP, ATP, or NMN in the presence or
absence of 2.5 mM EDTA/EGTA. After incubating at 4 or 37uC
for the indicated times, the amounts of these phosphated
compounds remaining in the plasma were determined, as
described above.
In situ NAMPT reaction in the plasma
Fresh plasma (30 ml) prepared without the addition of EDTA/
EGTA was incubated with recombinant NAMPT, PRPP, and
Figure 1. Metabolic pathways of the salvage NAD synthesis.
NaAD, NA adenine dinucleotide; NMNAT, NMN adenylyltransferase;
NaMNAT, NaMN adenylyltransferase; NADsyn, NAD synthetase. Broken
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2
(pH 7.5) at 37uC for 10 min. After the reaction was terminated by
adding an equal volume of PCA, the NMN that formed was
quantified, as described above.
Statistical analysis
Statistical data are expressed as the mean 6 S.D. of n
experiments.
Results
ATP is an essential activator of NAMPT reaction
We first determined Km values for the substrates Nam and PRPP
in the NAMPT reaction in the absence or presence of ATP. As
shown in Table 1, Km values for Nam and PRPP dramatically
decreased from 8.06 to 1.22 mM and from 23.2 to 0.51 mM,
respectively, in the presence of 1 mM ATP. Taken together with
the intracellular concentrations of Nam and PRPP (around 10 and
1 mM, respectively [19–21]), the kinetic data predicted that
NAMPT would exhibit significant activity only in the presence
of ATP under the intracellular condition. Indeed, when NAMPT
was incubated with 20 mM Nam and 1 mM PRPP in the presence
of 1 mM ATP, NMN formation was readily observed, whereas the
enzyme did not exhibit significant activity without ATP (Table 2).
In contrast, at much higher concentrations of Nam and PRPP
(50 mM), the enzyme exhibited significant activity even in the
absence of ATP (Table 2). These observations indicate that ATP is
an essential activator for NAMPT at the intracellular concentra-
tions of the substrates. As shown in Fig. 2, the millimolar levels of
ATP were required for significant activity of NAMPT under the
intracellular conditions. ADP, AMP, or NAD, each 1 mM in
concentration, did not exhibit the stimulatory effect on NAMPT
enzyme activity (data not shown). The similar requirement of ATP
was observed for human NAPRT, the NAD biosynthetic enzyme
also using PRPP as a substrate and ATP as an activator [4–6]
(Tables 1 and 2, and Fig. 2). Replacing His-213 of NAPRT [17],
which corresponds to His-219 in Salmonella typhimurium NAPRT
that is the key amino acid responsible for activation by ATP [22],
with Asn rendered the enzyme ATP-insensitive (Table 1).
In mouse blood plasma, although Nam is present, PRPP
and ATP are almost absent
We next investigated whether NAMPT exhibits in situ
enzymatic activity in an extracellular environment, blood plasma,
which has been reported to contain Nam [23] but little or no ATP
[16]. We determined concentrations of Nam, PRPP, and ATP in
freshly prepared mouse blood plasma and evaluated NAMPT
activity in the extracellular milieu, based on the kinetic parameters
determined above. Using LC/MS/MS analysis [18] and the
luciferin/luciferase method, we determined Nam and ATP
concentrations as 4.661.5 mM( n=3) and extremely low
(1.360.3 mM, n=3) in the plasma, respectively, which are
consistent with those previously reported in mammalian circula-
tion in general [16,23]. With NAPRT assay, plasma concentration
of PRPP was determined as below the limit of detection (,50 nM,
n=3). In marked contrast with the previous report [9], NMN was
not detected in the plasma (,50 nM, n=5) by LC/MS/MS
analysis.
It is well known that enzyme activities degrading phosphated
compounds, including ATP, are present in blood [16]. We might
not detect PRPP, ATP, and NMN in blood plasma because they
were rapidly degraded by the enzymes during the plasma
preparation. To test this possibility, we examined the stability of
PRPP, ATP, and NMN in the plasma. As shown in Fig. 3, these
compounds were not significantly degraded in the plasma for at
least 20 min in the presence of EDTA/EGTA at 4uC, the
conditions used to prepare plasma. After incubating even at 37uC,
they were largely protected from degradation (Fig. 3). In marked
contrast, PRPP and ATP were rapidly degraded in the plasma
without the addition of the chelators (Fig. 3). NMN was also
degraded in the absence of the chelators at 37uC, but more slowly
than PRPP or ATP (Fig. 3). These results indicate that although
PRPP, ATP, and NMN are degraded in the plasma, these
compounds are stable if plasma is maintained at 4uC in the
presence of the chelators, and thus the inability to detect these
compounds in the plasma is not due to their degradation during
the plasma preparation.
From all these observations, we conclude that in the mouse
blood plasma, although Nam is present, PRPP and ATP are
Table 1. Kinetic parameters in the NAMPT and NAPRT
reactions.
Enzyme Substrate Km (mM) Vmax (pmol/min/mg)
2ATP +ATP 2ATP +ATP
NAMPT Nam 8.0660.09 1.2260.21 39.3617.4 39.7614.1
PRPP 23.264.78 0.5160.16 25.965.1 74.1621.1
NAPRT NA 131615.1 19.664.5 63.9611.3 24.666.6
PRPP 88.0642.0 0.3760.14 41.1620.5 21.666.1
H213N-NAPRT NA 441628 430669 57.267.1 40.868.8
PRPP 5926165 6406189 68.568.4 54.769.1
NAMPT (36 ng) was incubated with various Nam concentrations at a fixed PRPP
concentration (300 mM) for 7 and 20 min in the presence or absence of 1 mM
ATP, respectively. The enzyme (7 and 36 ng) was also incubated with various
concentrations of PRPP at fixed Nam concentrations (5 and 40 mM) for 7 and
30 min in the presence or absence of 1 mM ATP, respectively. NAPRT (70 and
100 ng) was incubated with various NA concentrations at a fixed PRPP
concentration (300 mM) in the presence or absence of 1 mM ATP, respectively,
for 30 min. The enzyme (12 and 90 ng) was also incubated with various
concentrations of PRPP at fixed NA concentrations (50 and 380 mM) for 15 and
30 min in the presence or absence of 1 mM ATP, respectively. The mutant
NAPRT (H213N-NAPRT, 140 ng) was incubated with various NA concentrations
at a fixed PRPP concentration (600 mM) or with various concentrations of PRPP
at a fixed NA concentration (650 mM) in the presence or absence of 1 mM ATP
for 60 min. Km and Vmax values represent the mean 6 S.D. of at least three
separate experiments.
doi:10.1371/journal.pone.0022781.t001
Table 2. NAMPT and NAPRT activities in the absence or
presence of ATP.
Substrate concentration Enzyme Activity (pmol/min/mg)
2ATP +ATP
Low NAMPT 2.13 70.4
NAPRT 0.87 52.0
High NAMPT 25.9 48.1
NAPRT 9.67 19.3
NAMPT (15 ng) and NAPRT (20 ng) were incubated with 20 mM[
14C]Nam and
[
14C]NA for 30 min, respectively, in the presence of 1 mM PRPP (low substrate
concentration) without or with 1 mM ATP. NAMPT (96 ng) and NAPRT (100 ng)
were also incubated with 50 mM[
14C]Nam and [
14C]NA for 7 and 6 min,
respectively, in the presence of 50 mM PRPP (high substrate concentration)
without or with 1 mM ATP.
doi:10.1371/journal.pone.0022781.t002
Extracellular NAMPT Activity
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Nam and PRPP in the plasma compared with their intracellular
levels and the low affinity of NAMPT for the substrates in the
absence of ATP, NAMPT should not efficiently catalyze its
reaction in the plasma.
NAMPT does not form NMN in the blood plasma
To directly examine above notion, we incubated NAMPT with
the plasma and the formation of NMN was determined. Even
when NAMPT was incubated with the plasma at 25 mg/ml, a
concentration 10 thousand times higher than those in blood
plasma (1–3 ng/ml) [24,25], NMN formation was not observed
(n=3). However, upon further addition of PRPP (30 mM) together
with ATP (1 mM), a significant amount of NMN was synthesized
in the reaction (0.4260.07 mM, n=3). When only PRPP (30 mM)
was added to the plasma together with NAMPT, NMN formation
was not observed (n=3), confirming the essential requirement of
ATP for the NAMPT reaction. Under the condition, PRPP
remained in the plasma at 3.260.6 mM( n=3). These observations
indicate that NAMPT does not catalyze the NAMPT reaction in
the plasma without the addition of both PRPP and ATP.
Discussion
NAMPT is the rate-limiting enzyme catalyzing the first step of
NAD salvage synthesis in mammalian cells [1]. Also known as
visfatin, circulating NAMPT has been reported to exert a variety
of actions [8–11,15]. It has been proposed that possible
extracellular actions of visfatin are mediated through its NAMPT
activity [9,11,14,15]. However, extracellular spaces are reported to
contain little or no ATP [16]. We thus questioned whether visfatin
indeed catalyzes NMN formation under such extracellular milieus.
To address this question, it is crucially important to evaluate the
requirement of ATP for NAMPT under extra- as well as
intracellular conditions. Using purified recombinant human
NAMPT, we here demonstrated that ATP is an essential activator
of NAMPT at physiological concentrations of the substrates PRPP
and Nam.
Our kinetic analyses revealed that millimolar concentration of
ATP increases the affinity of NAMPT for Nam and PRPP. In
particular, Km value for PRPP was much higher than its
intracellular concentration in the absence of ATP, whereas in
the presence of 1 mM ATP, the Km value decreased to its
intracellular concentration. Consistent with the kinetic data,
NAMPT did not exhibit significant activity at intracellular
concentrations of the substrates without ATP whereas the enzyme
was dramatically activated in the presence of millimolar
Figure 3. PRPP, ATP, and NMN are degraded in mouse blood
plasma. PRPP, ATP, or NMN (150, 300, or 60 pmol, respectively) was
incubated with the blood plasma (30 ml) in the presence of EDTA/EGTA
at 4 (circles)o r3 7 uC( triangles) or in the absence of the chelators at 37uC
(squares) for the indicated times. After the incubation, the amounts of
PRPP (A), ATP (B), and NMN (C) remaining at each time point in the
plasma were determined and expressed as percent of those at 0 min.
doi:10.1371/journal.pone.0022781.g003
Figure 2. ATP is an essential activator of NAMPT and NAPRT reactions. NAMPT (A, 15 ng) and NAPRT (B, 20 ng) were incubated with 20 mM
[
14C]Nam and [
14C]NA for 6 and 7 min, respectively, in the presence of 1 mM PRPP and indicated concentrations of ATP. The amounts of NMN (A) and
NaMN (B) formed were determined. Data in figures 2 and 3 are representative of at least three experiments.
doi:10.1371/journal.pone.0022781.g002
Extracellular NAMPT Activity
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trations of the substrates, NAMPT activity was essentially
independent of the presence of ATP. These results indicate that
millimolar levels of ATP are absolutely required for NAMPT to
exhibit significant activity under intracellular milieu, whereas if
much higher concentrations of the substrates are available, the
nucleotide is not essential for the enzyme activity. Almost the same
requirement of ATP was confirmed for human NAPRT.
Mutagenesis study identified His-213 as a possible determinant
of the activation of NAPRT by ATP. Recently, a similar effect of
ATP on the NAMPT reaction has been reported by Burgos and
Schramm [26].
We for the first time provided ATP concentrations that produce
half-maximal stimulation (Ka) in NAMPT and NAPRT reactions
under the physiological condition (Fig. 2). The obtained Ka values
for ATP of NAMPT and NAPRT [341663 mM( n=5) and
395691 mM( n=3), respectively] were much higher than the
reported Km values for ATP of human NMN/NaMN adenylyl-
transferase-1, -2, and -3 (59, 89, and 42 mM, respectively) [27] and
NAD synthetase (89 mM) [28], the downstream enzymes in the
NAD salvage synthesis [1] (Fig. 1). Comparison of these kinetic
data revealed that NAMPT and NAPRT are the most sensitive
enzymes to changes in cellular ATP levels in the salvage synthesis
of NAD. Thus, it is likely that the synthesis of NAD is tightly
regulated at the first steps of the pathway by the cellular
concentration of ATP, and that based on the millimolar levels of
normal cellular ATP this regulation may be significant during
substantial depletion of ATP pools, such as that during cellular
stress.
It has been hypothesized that visfatin acts as an extracellular
NMN-forming enzyme and the resulting NMN is used for
intracellular NAD biosynthesis after taken up by cells
[9,11,14,15]. However, our study here provides three lines of
evidence that do not support this hypothesis. Firstly, the essential
requirement of ATP for NAMPT activity does not support
NAMPT to catalyze NMN formation in the extracellular milieus.
In mouse blood plasma, although the substrate Nam was present
at a concentration of 4.6 mM, the other substrate PRPP was not
detected and the activator ATP was almost absent (1.3 mM).
Taken together with the low affinity of NAMPT for the substrates
in the absence of the activator ATP as well as much lower
concentrations of the substrates in the blood plasma compared
with their intracellular levels, NAMPT should not efficiently
catalyze its reaction in the plasma. Secondly, we found that PRPP
is rapidly degraded in the plasma. Since the addition of EDTA/
EGTA to the plasma inhibited the degradation of PRPP, alkaline
phosphatases, with broad substrate specificity towards various
phosphated compounds and requirement of metal ions for enzyme
activity [16], may at least in part catalyze the degradation. The
strong PRPP-degrading enzyme activity in the plasma, as well as
the reported short half-life of ATP in the extracellular milieu
[16,29], confirmed in this study, excludes the possibility that
extracellular concentrations of PRPP and ATP might rise high
enough to support NMN synthesis, such as in the microenviron-
ment of damaged cells. Thirdly, NAMPT added to the plasma did
not catalyze NMN formation. The inability to detect NAMPT
activity was not due to a small amount of the enzyme added or the
inactivation of the enzyme in the plasma, since the enzyme was
added to the plasma at a concentration 10 thousand times higher
than those in blood plasma [24,25] and a significant amount of
NMN was produced by the addition of PRPP and ATP. These
results indicate that NAMPT did not catalyze its reaction in the
plasma because of the extremely low concentrations of PRPP and
ATP. Thus, NAMPT does not participate in NMN formation
under such extracellular milieus. All three lines of evidence
provided here indicate that extracellular visfatin can not be
considered as an enzyme capable of synthesizing NMN.
We did not detect NMN in the plasma, even with a highly
specific and sensitive LC/MS/MS method [18] that can quantify
NMN if the mononucleotide is present at a concentration of at
least 50 nM. The inability to detect NMN in the plasma is not due
to its degradation during the plasma preparation because the
nucleotide was stable under the conditions used to prepare plasma.
In marked contrast with the present result, previous studies have
reported NMN concentrations in blood plasma to be 80–90 mM
[9] and culture medium of the muscle cells to be 300 mM [15],
using HPLC analysis with UV absorbance detection. The reported
high extracellular concentrations of NMN might be arisen from
the difficulty of the quantification of NMN by HPLC analysis
because of its extremely short elution time [30].
In conclusion, the essential requirement of ATP for NAMPT
activity and the inability of NAMPT added to the mouse blood
plasma to form NMN indicate that extracellular environments
with little or no ATP do not allow extracellular visfatin to catalyze
the in situ formation of NMN. In addition, extracellular NMN does
not serve as a direct precursor of intracellular NAD biosynthesis
[31]. Collectively, these observations do not support the concept of
‘‘NAMPT-mediated systemic NAD biosynthesis’’ [9,14]. The
presence of visfatin in circulation may merely be the result of
cell death [32], or even if plasma visfatin has physiological
functions it may act independent of its NMN biosynthetic activity
[33]. Our study would help to clarify physiological significance of
extracellular NAMPT.
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